Times of crisis and opportunity
Much of the research and innovation response to COVID-19 has been international
The science and innovation response to COVID-19 has been a mix of national and international efforts. By August 2020, about USD 2 billion (a mix of public and private money) had been pledged for international research efforts (Figure 1), mostly through the Coalition for Epidemic Preparedness Innovation (CEPI) and the Global Alliance for Vaccines and Immunization (GAVI) for developing COVID-19 vaccines. These efforts have built on recent and previously untested technological and institutional innovations at the global level that have enabled the rapid development of vaccines. The United States and China are among the two major contributors to COVID-19 publications (Figure 8), and about a quarter of their publications are co-authored with researchers based in another country. Other countries with high engagement in international research collaborations on COVID-19 include the United Kingdom, Germany, France, Italy, Australia, Canada and India.
International scientific collaboration on COVID-19 biomedical research
Whole counts, January to November 30, 2020
Source: OECD and OCTS-OEI calculations based on US National Institutes of Health PubMed data (accessed 30 November 2020). StatLink https://doi.org/10.1787/888934223099
- Governments acted quickly to fund COVID-19-related research and innovation at scale
- The pandemic has triggered an unprecedented mobilisation of the scientific community
- Despite the disruption, scientists have continued their work during the crisis
- Responses to the crisis have drawn upon the innovative potential of businesses
- Business research and innovation have been impacted unevenly by the crisis
- Much of the research and innovation response to COVID-19 has been international
‹ Homepage
Related Documents
- Postgraduate training regimes need reforming to support a diversity of career paths
- Responses to the crisis have drawn upon the innovative potential of businesses
- The pandemic has triggered an unprecedented mobilisation of the scientific community
- Growing government debt could lead to austerity, and some hard choices for research and innovation policy
- Government R&D expenditures may need to shift to reflect new priorities
- Business research and innovation have been affected unevenly by the crisis
- Building government capabilities to meet future challenges will be a major challenge in itself
- Global challenges require global solutions
- Despite the disruption, scientists have continued their work during the crisis
- The STI policy mix needs to be more targeted
- Governments acted quickly to fund COVID-19-related research and innovation at scale